<DOC>
	<DOCNO>NCT01616459</DOCNO>
	<brief_summary>The purpose study assess immunogenicity , reactogenicity safety two formulation GSK Biologicals ' pneumococcal vaccine ( 2830929A 2830930A ) administer 3-dose primary vaccination first 6 month life follow booster dose second year life . To comply routine infant immunisation program , license GSK Biologicals DTPa-HBV-IPV/Hib ( Infanrix hexa ) vaccine co-administered infant pneumococcal study vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety Two Formulations GSK Biologicals ' Pneumococcal Vaccine ( 2830929A 2830930A ) When Administered Healthy Infants</brief_title>
	<detailed_description>The purpose study assess immunogenicity two formulation GSK Biologicals ' pneumococcal vaccine 2830929A ( 11-valent vaccine 11Pn vaccine ) 2830930A ( 12-valent vaccine 12Pn vaccine ) , administer 3-dose primary vaccination first 6 month life follow booster dose second year life , compare immune response license vaccine Synflorix™ Prevnar 13™ , assess reactogenicity safety two investigational formulation administer accord schedule . To comply routine infant immunisation program , license GSK Biologicals DTPa-HBV-IPV/Hib ( Infanrix hexa™ ) vaccine co-administered infant pneumococcal study vaccine .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LARs ) comply requirement protocol . A male female , include 6 12 week ( 4290 day ) age time first vaccination . In addition , first pneumococcal DTPaHBVIPV/Hib vaccination give accordance official national recommendation immunisation schedule infant . Written inform consent obtain parents/LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Born gestation period least 36 week . Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/administration vaccine contain diphtheria toxoid , tetanus toxoid ( except MenCTT Spain ) CRM197 foreseen study protocol time study period , vaccine foresee protocol period start 30 day dose end 30 day dose vaccine ( ) , follow exception : Licensed influenza vaccine always allow , even concomitantly administer study vaccine . Licensed rotavirus vaccine allow administer least 7 day dose study vaccine . Licensed MenCTT vaccine allow Spain concomitantly administer study vaccine around 2 , 4 1215 month age . In case emergency mass vaccination unforeseen public health threat ( e.g . pandemic ) organise public health authority , outside routine immunization program , vaccine administer time study period provide license used accord Summary Product Characteristics Prescribing Information accord local governmental recommendation . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness , include Kawasaki 's syndrome . History neurological disorder seizure , include condition hypotensivehyporesponsive episode , encephalopathy convulsion ( afebrile febrile ) . Acute disease and/or fever time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period . Previous vaccination diphtheria , tetanus , pertussis , polio , H. influenzae type b . Previous vaccination S. pneumoniae . History intercurrent diphtheria , tetanus , pertussis , hepatitis B , polio , H. influenzae type b disease . Any medical condition might interfere assessment study objective opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Haemophilus influenzae</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Infants</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>